Bristol Myers Squibb Stock Fundamentals
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol-Myers Squibb's financial success or failures. It also enables traders to predict the movement of Bristol-Myers Pink Sheet. The fundamental analysis module provides a way to measure Bristol-Myers Squibb's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol-Myers Squibb pink sheet.
Bristol-Myers |
Bristol Myers Squibb Company Cash And Equivalents Analysis
Bristol-Myers Squibb's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Bristol-Myers Squibb Cash And Equivalents | 6.07 B |
Most of Bristol-Myers Squibb's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Bristol Myers Squibb has 6.07 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and 10.18% lower than that of the Drug Manufacturers - Major industry. The cash and equivalents for all United States stocks is 124.64% lower than that of the firm.
Bristol Myers Squibb Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bristol-Myers Squibb's current stock value. Our valuation model uses many indicators to compare Bristol-Myers Squibb value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol-Myers Squibb competition to find correlations between indicators driving Bristol-Myers Squibb's intrinsic value. More Info.Bristol Myers Squibb is the top company in revenue category among related companies. It is number one stock in ebitda category among related companies totaling about 0.43 of EBITDA per Revenue. The ratio of Revenue to EBITDA for Bristol Myers Squibb is roughly 2.31 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol-Myers Squibb by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol-Myers Squibb's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol-Myers Squibb's earnings, one of the primary drivers of an investment's value.Bristol-Myers Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol-Myers Squibb's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol-Myers Squibb could also be used in its relative valuation, which is a method of valuing Bristol-Myers Squibb by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in cash and equivalents category among related companies.
Bristol-Myers Fundamentals
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B | |||
| Number Of Employees | 23.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 2.11 T | |||
| Total Asset | 109.31 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 109.31 B | |||
| Last Dividend Paid | 1.59 |
Pair Trading with Bristol-Myers Squibb
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Salesforce could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Salesforce when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Salesforce - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Salesforce to buy it.
The correlation of Salesforce is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Salesforce moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Salesforce moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Salesforce can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Bristol-Myers Pink Sheet
If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |